CSSPF (NIOX Group) Debt-to-Revenue : 0.02 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CSSPF NIOX Group PLC CSSPF
77 GF Score
Price $0.82
GF Value $1.23
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is NIOX Group Debt-to-Revenue?

NIOX Group CSSPF 77 Debt-to-Revenue is 0.02 as of Dec. 2025. GuruFocus rates CSSPF with a GF Score™ of 77/100 and a GF Value™ of $1.23 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Debt-to-Revenue measures a company's ability to pay off its debt.

NIOX Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was $0.67 Mil. NIOX Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was $0.67 Mil. NIOX Group's annualized Revenue for the quarter that ended in Dec. 2025 was $62.92 Mil. NIOX Group's annualized Debt-to-Revenue for the quarter that ended in Dec. 2025 was 0.02.

NIOX Group Debt-to-Revenue Historical Data

* Premium members only.

The historical data trend for NIOX Group's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NIOX Group Debt-to-Revenue Chart

NIOX Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 0.03 0.03 0.04 0.02

NIOX Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.02 0.04 0.02 0.02

CSSPF vs ABT, SYK, MDT: Debt-to-Revenue Comparison

For the Medical Devices subindustry, NIOX Group's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NIOX Group Debt-to-Revenue vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NIOX Group's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where NIOX Group's Debt-to-Revenue falls into.


CSSPF
77GF Score
NIOX Group PLC CSSPF
Debt-to-Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NIOX Group Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

NIOX Group's Debt-to-Revenue for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.669 + 0.669) / 65.194
=0.02

NIOX Group's annualized Debt-to-Revenue for the quarter that ended in Dec. 2025 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.669 + 0.669) / 62.918
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2025) Revenue data.

Frequently Asked Questions Learn more about Debt-to-Revenue →
What does a Debt-to-Revenue of 0.02 mean?
NIOX Group (CSSPF) has a Debt-to-Revenue of 0.02 as of Dec. 2025.
Is NIOX Group's Debt-to-Revenue too high?
NIOX Group's current Debt-to-Revenue is 0.02. Overall, NIOX Group has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NIOX Group's Debt-to-Revenue compare to ABT and SYK?
NIOX Group's Debt-to-Revenue of 0.02 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Revenue for a Medical Devices & Instruments company?
A good Debt-to-Revenue depends on the Medical Devices & Instruments industry context. However, Debt-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Revenue mean?
A high Debt-to-Revenue can signal that a stock is expensive relative to its fundamentals. NIOX Group's current Debt-to-Revenue is 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NIOX Group stock overvalued right now?
Based on GuruFocus' analysis, NIOX Group (CSSPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $1.23, compared to a current price of $0.82 — trading 33.3% below its estimated fair value. The current Debt-to-Revenue is 0.02. NIOX Group's overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Revenue calculated?
Debt-to-Revenue is calculated from a company's financial statements. For NIOX Group (CSSPF), the current Debt-to-Revenue is 0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NIOX Group (CSSPF) Overvalued in 2026?

Based on GuruFocus' analysis, NIOX Group stock appears to be undervalued. The current stock price of $0.82 is trading 33.3% below its estimated GF Value™ of $1.23. GuruFocus considers NIOX Group to be Significantly Undervalued.

Key valuation signals for CSSPF:

  • Debt-to-Revenue: 0.02
  • GF Value™: $1.23 vs. price of $0.82 (33.3% below fair value)
  • GF Score™: 77/100 with 2 warning signs

No single metric tells the full story. See the CSSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NIOX Group Business Description

Other Exchanges NIOXl:UKNIOX:UK82C:Germany
Address 1 Robert Robinson Avenue, Magdalen Centre, The Oxford Science Park, Oxford, GBR, OX4 4GA
NIOX Group PLC is engaged in improving the diagnosis, monitoring and management of both asthma and COPD by providing greater patient access to FeNO testing. The company is engaged in the design, development, and commercialization of medical devices for the measurement of FeNO, a precise biomarker for type 2 inflammation which is present in asthma and COPD. Its device, NIOX VERO, is increasingly recognised by healthcare professionals as an important tool to improve the diagnosis, monitoring and management of asthma and COPD. It operates in single segment of NIOX relates to the portfolio of products used to improve asthma diagnosis, monitoring and management by measuring fractional exhaled nitric oxide (FeNO).
77GF Score

Get the complete analysis for CSSPF

Debt-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.82
Price
$1.23
GF Value